Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions. However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption.
By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross US$ 1 Bn in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels.
While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.
Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives.
Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.
Principal Consultant
Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals prefer hormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer.
That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.
The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The endometriosis treatment market is likely to secure a CAGR of 10.6% through 2032.
The endometriosis treatment market size is estimated to cross US$ 3.55 Billion by 2032.
The endometriosis treatment market is likely to record a value of US$ 1.30 Billion in 2022.
Europe is likely to lead the endometriosis treatment market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Drug Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Endometriosis Epidemiology, By Key Region
4.3. Unmet Needs of Endometriosis Treatment
4.3.1. Potential Diagnostic Biomarkers for Endometriosis
4.3.1.1. Existing & Emerging Non-invasive Diagnostics Techniques
4.3.2. Disease Awareness and Educational Strategies for Medical Professionals
4.3.3. Drug Effectivity & Safety, By Drug
4.3.4. Marketed & Emerging Non-hormonal Therapies for Endometriosis
4.3.5. Disease Etiology and Pathophysiology
4.4. Research and Development Strategies
4.4.1. Reformulations and Label Expansion of Currently Marketed Drugs
4.4.2. Pipeline Assessment of GnRH Antagonists
4.4.3. Pipeline Assessment of Novel Non-hormonal Therapies
4.4.4. Key Strategies Followed By Manufacturers (Alliance, In-Licensing and Out-Licensing Strategies)
4.4.5. Strategy to Maximise Return on Investment (Drug Approvals for Secondary Indication)
4.5. Attributes/Factors Important in Clinical Trials
4.6. Clinical Trial History of Key Marketed Drugs
4.7. Attributes/Factors considered for Market Sizing of Historical Market Sizing & Opportunity Assessment of Pipeline Drugs
4.8. Pipeline Assessment/Clinical Benchmark Analysis
4.8.1. Marketed Drug/Pipeline Valuation Analysis
4.8.1.1. Therapeutic Advantages by Drug
4.8.1.2. New Drug Launches and Regulatory Approvals, 2019-2030
4.8.1.3. Opportunity Assessment in terms of Revenue, 2020-2025
4.8.1.4. Clinical Trials and Pipeline Overview
4.9. Regulatory Scenario
4.10. Reimbursement Scenario
4.11. Primary Verbatim, Key Opinion Leaders Opinion on Future Opportunities
5. Global Market Demand (Size in US$ Mn) Analysis 2014-2018 and Opportunity Assessment, 2019-2030
5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2030
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Global Healthcare Outlook
6.1.3. Per Capita Healthcare Expenditure Outlook
6.2. Opportunity Assessment Factors - Relevance & Impact
6.2.1. Prevalence of Endometriosis
6.2.2. Growing Healthcare Expenditure
6.2.3. Increasing Number of Clinical Trials
6.2.4. Regulatory Policy Changes
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
7. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Drug
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Drug, 2014-2018
7.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Drug, 2019-2030
7.3.1. Oral Contraceptives
7.3.2. Progestins
7.3.3. NSAIDs
7.3.4. GnRH Analogues
7.3.5. LNR-IUDs
7.3.6. Others
7.4. Market Attractiveness Analysis By Drug
8. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Treatment Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2014-2018
8.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Treatment Type, 2019-2030
8.3.1. Hormonal Therapy
8.3.2. Pain management
8.4. Market Attractiveness Analysis By Treatment Type
9. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014-2018
9.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Distribution Channel, 2019-2030
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Drugstores
9.3.4. E-commerce
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018
10.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Region, 2019-2030
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
11.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug
11.3.3. By Treatment Type
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug
11.4.3. By Treatment Type
11.4.4. By Distribution Channel
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
12.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug
12.3.3. By Treatment Type
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug
12.4.3. By Treatment Type
12.4.4. By Distribution Channel
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
13.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug
13.3.3. By Treatment Type
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Treatment Type
13.4.4. By Distribution Channel
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. South Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
14.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Drug
14.3.3. By Treatment Type
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Treatment Type
14.4.4. By Distribution Channel
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. East Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
15.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug
15.3.3. By Treatment Type
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Treatment Type
15.4.4. By Distribution Channel
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Oceania Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
16.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug
16.3.3. By Treatment Type
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Treatment Type
16.4.4. By Distribution Channel
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Middle East and Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
17.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. Northern Africa
17.3.1.4. South Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Drug
17.3.3. By Treatment Type
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Treatment Type
17.4.4. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Emerging Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. India Market Analysis
18.2.1. Introduction
18.2.2. PEST Analysis
18.2.3. Market Value Analysis by Market Taxonomy
18.2.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy
18.2.4.1. By Drug
18.2.4.2. By Treatment Type
18.2.4.3. By Distribution Channel
18.3. China Market Analysis
18.3.1. Introduction
18.3.2. PEST Analysis
18.3.3. Market Value Analysis by Market Taxonomy
18.3.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy
18.3.4.1. Drug
18.3.4.2. By Treatment Type
18.3.4.3. By Distribution Channel
18.4. Brazil Market Analysis
18.4.1. Introduction
18.4.2. PEST Analysis
18.4.3. Market Value Analysis by Market Taxonomy
18.4.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy
18.4.4.1. By Drug
18.4.4.2. By Treatment Type
18.4.4.3. By Distribution Channel
19. U.S. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
19.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
19.3.1. By Drug
19.3.2. By Treatment Type
19.3.3. By Distribution Channel
19.4. Market Attractiveness Analysis
20. Canada Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
20.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
20.3.1. By Drug
20.3.2. By Treatment Type
20.3.3. By Distribution Channel
20.4. Market Attractiveness Analysis
21. Mexico Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
21.1. Introduction
21.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
21.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
21.3.1. By Drug
21.3.2. By Treatment Type
21.3.3. By Distribution Channel
21.4. Market Attractiveness Analysis
22. Germany Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
22.1. Introduction
22.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
22.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
22.3.1. By Drug
22.3.2. By Treatment Type
22.3.3. By Distribution Channel
22.4. Market Attractiveness Analysis
23. U.K. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
23.1. Introduction
23.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
23.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
23.3.1. By Drug
23.3.2. By Treatment Type
23.3.3. By Distribution Channel
23.4. Market Attractiveness Analysis
24. France Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
24.1. Introduction
24.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
24.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
24.3.1. By Drug
24.3.2. By Treatment Type
24.3.3. By Distribution Channel
24.4. Market Attractiveness Analysis
25. Italy Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
25.1. Introduction
25.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
25.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
25.3.1. By Drug
25.3.2. By Treatment Type
25.3.3. By Distribution Channel
25.4. Market Attractiveness Analysis
26. Spain Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
26.1. Introduction
26.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
26.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
26.3.1. By Drug
26.3.2. By Treatment Type
26.3.3. By Distribution Channel
26.4. Market Attractiveness Analysis
27. Russia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
27.1. Introduction
27.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
27.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
27.3.1. By Drug
27.3.2. By Treatment Type
27.3.3. By Distribution Channel
27.4. Market Attractiveness Analysis
27.5. Market Attractiveness Analysis
28. Japan Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
28.1. Introduction
28.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
28.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
28.3.1. By Drug
28.3.2. By Treatment Type
28.3.3. By Distribution Channel
28.4. Market Attractiveness Analysis
29. South Korea Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
29.1. Introduction
29.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
29.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
29.3.1. By Drug
29.3.2. By Treatment Type
29.3.3. By Distribution Channel
29.4. Market Attractiveness Analysis
30. Australia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
30.1. Introduction
30.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
30.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
30.3.1. By Drug
30.3.2. By Treatment Type
30.3.3. By Distribution Channel
30.4. Market Attractiveness Analysis
31. New Zealand Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
31.1. Introduction
31.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
31.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
31.3.1. By Drug
31.3.2. By Treatment Type
31.3.3. By Distribution Channel
31.4. Market Attractiveness Analysis
32. GCC Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
32.1. Introduction
32.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
32.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
32.3.1. By Drug
32.3.2. By Treatment Type
32.3.3. By Distribution Channel
32.4. Market Attractiveness Analysis
33. South Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030
33.1. Introduction
33.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018
33.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030
33.3.1. By Drug
33.3.2. By Treatment Type
33.3.3. By Distribution Channel
33.4. Market Attractiveness Analysis
34. Market Structure Analysis
34.1. Market Analysis by Tier of Companies
34.2. Market Share Analysis of Top Players
34.3. Company Share Analysis
34.4. Market Presence Analysis
34.4.1. By Regional footprint of Players
34.4.2. Channel Foot Print by Players
35. Competition Analysis
35.1. Competition Dashboard
35.2. Competition Benchmarking
35.3. Competition Deep Dive (Tentative List)
35.3.1. AbbVie Inc.
35.3.1.1. Overview
35.3.1.2. Service Portfolio
35.3.1.3. Profitability by Market Segments (Service/Channel/Region)
35.3.1.4. Sales Footprint
35.3.1.5. Strategy Overview
35.3.1.5.1. Marketing Strategy
35.3.1.5.2. Service Strategy
35.3.1.5.3. Channel Strategy
35.3.2. Bayer AG
35.3.2.1. Overview
35.3.2.2. Service Portfolio
35.3.2.3. Profitability by Market Segments (Service/Channel/Region)
35.3.2.4. Sales Footprint
35.3.2.5. Strategy Overview
35.3.2.5.1. Marketing Strategy
35.3.2.5.2. Service Strategy
35.3.2.5.3. Channel Strategy
35.3.3. AstraZeneca
35.3.3.1. Overview
35.3.3.2. Service Portfolio
35.3.3.3. Profitability by Market Segments (Service/Channel/Region)
35.3.3.4. Sales Footprint
35.3.3.5. Strategy Overview
35.3.3.5.1. Marketing Strategy
35.3.3.5.2. Service Strategy
35.3.3.5.3. Channel Strategy
35.3.4. Pfizer Inc.
35.3.4.1. Overview
35.3.4.2. Service Portfolio
35.3.4.3. Profitability by Market Segments (Service/Channel/Region)
35.3.4.4. Sales Footprint
35.3.4.5. Strategy Overview
35.3.4.5.1. Marketing Strategy
35.3.4.5.2. Service Strategy
35.3.4.5.3. Channel Strategy
35.3.5. Teva Pharmaceutical Industries Ltd.
35.3.5.1. Overview
35.3.5.2. Service Portfolio
35.3.5.3. Profitability by Market Segments (Service/Channel/Region)
35.3.5.4. Sales Footprint
35.3.5.5. Strategy Overview
35.3.5.5.1. Marketing Strategy
35.3.5.5.2. Service Strategy
35.3.5.5.3. Channel Strategy
35.3.6. Ipsen Pharma
35.3.6.1. Overview
35.3.6.2. Service Portfolio
35.3.6.3. Profitability by Market Segments (Service/Channel/Region)
35.3.6.4. Sales Footprint
35.3.6.5. Strategy Overview
35.3.6.5.1. Marketing Strategy
35.3.6.5.2. Service Strategy
35.3.6.5.3. Channel Strategy
35.3.7. Myovant Sciences
35.3.7.1. Overview
35.3.7.2. Service Portfolio
35.3.7.3. Profitability by Market Segments (Service/Channel/Region)
35.3.7.4. Sales Footprint
35.3.7.5. Strategy Overview
35.3.7.5.1. Marketing Strategy
35.3.7.5.2. Service Strategy
35.3.7.5.3. Channel Strategy
35.3.8. Endoceutics, Inc.
35.3.8.1. Overview
35.3.8.2. Service Portfolio
35.3.8.3. Profitability by Market Segments (Service/Channel/Region)
35.3.8.4. Sales Footprint
35.3.8.5. Strategy Overview
35.3.8.5.1. Marketing Strategy
35.3.8.5.2. Service Strategy
35.3.8.5.3. Channel Strategy
35.3.9. Debiopharm Group
35.3.9.1. Overview
35.3.9.2. Service Portfolio
35.3.9.3. Profitability by Market Segments (Service/Channel/Region)
35.3.9.4. Sales Footprint
35.3.9.5. Strategy Overview
35.3.9.5.1. Marketing Strategy
35.3.9.5.2. Service Strategy
35.3.9.5.3. Channel Strategy
35.3.10. Mayne Pharma Group Limited
35.3.10.1. Overview
35.3.10.2. Service Portfolio
35.3.10.3. Profitability by Market Segments (Service/Channel/Region)
35.3.10.4. Sales Footprint
35.3.10.5. Strategy Overview
35.3.10.5.1. Marketing Strategy
35.3.10.5.2. Service Strategy
35.3.10.5.3. Channel Strategy
35.3.11. Noven Pharmaceuticals, Inc.
35.3.11.1. Overview
35.3.11.2. Service Portfolio
35.3.11.3. Profitability by Market Segments (Service/Channel/Region)
35.3.11.4. Sales Footprint
35.3.11.5. Strategy Overview
35.3.11.5.1. Marketing Strategy
35.3.11.5.2. Service Strategy
35.3.11.5.3. Channel Strategy
35.3.12. Sun Pharmaceutical Industries Limited
35.3.12.1. Overview
35.3.12.2. Service Portfolio
35.3.12.3. Profitability by Market Segments (Service/Channel/Region)
35.3.12.4. Sales Footprint
35.3.12.5. Strategy Overview
35.3.12.5.1. Marketing Strategy
35.3.12.5.2. Service Strategy
35.3.12.5.3. Channel Strategy
35.3.13. Amneal Pharmaceuticals, Inc. Market_Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2030
35.3.13.1. Overview
35.3.13.2. Service Portfolio
35.3.13.3. Profitability by Market Segments (Service/Channel/Region)
35.3.13.4. Sales Footprint
35.3.13.5. Strategy Overview
35.3.13.5.1. Marketing Strategy
35.3.13.5.2. Service Strategy
35.3.13.5.3. Channel Strategy
35.3.14. Mylan N.V.
35.3.14.1. Overview
35.3.14.2. Service Portfolio
35.3.14.3. Profitability by Market Segments (Service/Channel/Region)
35.3.14.4. Sales Footprint
35.3.14.5. Strategy Overview
35.3.14.5.1. Marketing Strategy
35.3.14.5.2. Service Strategy
35.3.14.5.3. Channel Strategy
35.3.15. Aurobindo Pharma
35.3.15.1. Overview
35.3.15.2. Service Portfolio
35.3.15.3. Profitability by Market Segments (Service/Channel/Region)
35.3.15.4. Sales Footprint
35.3.15.5. Strategy Overview
35.3.15.5.1. Marketing Strategy
35.3.15.5.2. Service Strategy
35.3.15.5.3. Channel Strategy
36. Assumptions and Acronyms Used
37. Research Methodology
Explore Healthcare Insights
View Reports
Endometriosis Treatment Market
